Compass Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Compass Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2018 to 2023.
  • Compass Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$12.2M, a 2.63% decline year-over-year.
  • Compass Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$55.4M, a 15.8% decline year-over-year.
  • Compass Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$50.4M, a 20.9% decline from 2022.
  • Compass Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$41.7M, a 49.1% increase from 2021.
  • Compass Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$81.9M, a 194% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$50.4M -$8.71M -20.9% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-21
2022 -$41.7M +$40.2M +49.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-21
2021 -$81.9M -$54.1M -194% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-15
2020 -$27.8M +$6.24M +18.3% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-18
2019 -$34.1M -$34M -103847% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-05
2018 -$32.8K Apr 1, 2018 Mar 31, 2019 10-K 2020-06-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.